LEADER 01657nam0 2200409 450 001 000043851 005 20180629094729.0 100 $a20180108d1985----km-y0itaa50------ba 101 0 $afre 102 $aFR 200 1 $aFleur en Fiole d'Or$fpréface par Étiemble$gintroduction par André Lévy$gtexte traduit, présenté et annoté par André Lévy 210 $a[Parigi]$cGallimard$d1985 215 $a2 volumi$d18 cm 225 2 $aBibliotèque de la Pléiade 327 11$aVol. 1: CXLIX, 1272 p.$aVol. 2: LIX, 1483 p. 410 0$12001$aBibliotèque de la Pléiade 510 1 $aJin Ping Mei cihua 676 $a895.13$v21.$zita 702 1$aÉtiemble,$bRené$f<1909-2002> 702 1$aLévy,$bAndré$f<1925- > 801 0$aIT$bUniversità della Basilicata - B.I.A.$gREICAT$2unimarc 912 $a000043851 996 $aFleur en Fiole d'Or$91532414 997 $aUNIBAS BAS $aLETTERE CAT $aMDL$b30$c20180108$lBAS01$h1142 CAT $aMDL$b30$c20180108$lBAS01$h1148 CAT $aMDL$b00$c20180110$lBAS01$h1050 CAT $aATR$b20$c20180614$lBAS01$h1052 CAT $aATR$b20$c20180614$lBAS01$h1053 CAT $aATR$b20$c20180614$lBAS01$h1058 CAT $aATR$b20$c20180614$lBAS01$h1059 CAT $aATR$b20$c20180614$lBAS01$h1118 CAT $aATR$b20$c20180629$lBAS01$h0947 FMT Z30 -1$lBAS01$LBAS01$mBOOK$1BASA1$APolo Storico-Umanistico$2GEN$BCollezione generale$3FP/56474$656474$5L56474$820180108$f02$FPrestabile Generale$hvolume 1 Z30 -1$lBAS01$LBAS01$mBOOK$1BASA1$APolo Storico-Umanistico$2GEN$BCollezione generale$3FP/56475$656475$5L56475$820180108$f02$FPrestabile Generale$hvolume 2 LEADER 02759nam 2200625Ia 450 001 9910451261203321 005 20200520144314.0 010 $a1-280-52556-8 010 $a0-19-536179-2 010 $a1-4294-1091-4 035 $a(CKB)1000000000410178 035 $a(EBL)272795 035 $a(OCoLC)466428036 035 $a(SSID)ssj0000101779 035 $a(PQKBManifestationID)11108552 035 $a(PQKBTitleCode)TC0000101779 035 $a(PQKBWorkID)10049199 035 $a(PQKB)10867410 035 $a(MiAaPQ)EBC272795 035 $a(Au-PeEL)EBL272795 035 $a(CaPaEBR)ebr10279122 035 $a(CaONFJC)MIL52556 035 $a(EXLCZ)991000000000410178 100 $a19940718d1995 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe ambassadors and America's Soviet policy$b[electronic resource] /$fDavid Mayers 210 $aNew York $cOxford University Press$d1995 215 $a1 online resource (viii, 335 pages) $cillustrations 300 $aDescription based upon print version of record. 311 $a0-19-511576-7 311 $a0-19-506802-5 320 $aIncludes bibliographical references (p. 307-322) and index. 327 $aContents; United States Chiefs of Mission in St. Petersburg and Moscow; Introduction; I: Before Moscow; 1. St. Petersburg and the U.S. Diplomatic Tradition; 2. From Comity to Estrangement; 3. War and Revolution; II: In Stalin's Time; 4. Preparing for Moscow; 5. Purges and the Failure of Collective Security; 6. Fragile Coalition; 7. Neither War Nor Peace; III: Great Power Rivalry; 8. After Stalin; 9. Controlled Rivalry; 10. Collapse and the Art of Diplomacy; Notes; Bibliography; Index; 330 $aMayers analyses the entire history of American foreign relations with Russia and then the Soviet Union, using the drama of the lives of the men and women who worked at the American embassy in Moscow to tell his story. Particular attention is paid to the critical events of the twentieth century. 410 0$aOUP E-Books. 606 $aAmbassadors$zUnited States$xHistory$y20th century 606 $aAmbassadors$zSoviet Union$xHistory 607 $aUnited States$xForeign relations$zSoviet Union 607 $aSoviet Union$xForeign relations$zUnited States 608 $aElectronic books. 615 0$aAmbassadors$xHistory 615 0$aAmbassadors$xHistory. 676 $a327.73047 700 $aMayers$b David Allan$f1951-$0539637 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451261203321 996 $aThe ambassadors and America's Soviet policy$91987054 997 $aUNINA LEADER 09728nam 22005773 450 001 9910825895903321 005 20210901203627.0 010 $a1-68108-805-3 024 7 $a10.2174/97816810880511210101 035 $a(CKB)4100000011979572 035 $a(MiAaPQ)EBC6676568 035 $a(Au-PeEL)EBL6676568 035 $a(OCoLC)1260348506 035 $a(NjHacI)994100000011979572 035 $a(BIP)080871517 035 $a(PPN)270291377 035 $a(EXLCZ)994100000011979572 100 $a20210901d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCOVID-19 205 $a1st ed. 210 1$aSharjah :$cBentham Science Publishers,$d2021. 210 4$d©2021. 215 $a1 online resource (225 pages) 311 $a1-68108-807-X 327 $aCover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19. 327 $aHydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19. 327 $aPARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT. 327 $aBENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover. 330 $aThe coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and much time has passed since it was declared as a pandemic by the World Health Organization (WHO). COVID-19: Diagnosis and Management provides clinicians and scholars all the information on this disease in 2 volumes. Readers will find a concise and visual reference for this viral disease and will be equipped with the knowledge to assess and manage Sar-Cov-2 infection cases in clinical settings. This book is divided into two parts (I and II). Part I provides comprehensive information about 1 History of Coronaviruses, 2 Epidemiology of COVID-19, 3 Clinical presentation of this viral disease and 4 COVID-19 diagnosis. Part II covers broader topics about this communicable disease including 1 the prevention and treatment methodology, 2 mortality and long-term complications, 3 COVID-19 vaccines and future perspectives. Key Features: - Covers all the aspects of COVID-19 making this a perfect textbook for virology and medical students. -Chapter wise description and segregation of topics from pathophysiology to diagnosis and management of COVID-19. -Six chapters in the first part which focus on clinical basics of COVID-19. -Six chapters in the second part which cover broader topics for practical infection control. -Multiple tables and figures which summarize and highlight important points. -Presents a summary of the current standards for the evaluation and diagnosis of COVID-19. - Features a detailed list of references, abbreviations, and symbols. This book is an essential textbook reference for medical students, scientists (virologists, pulmonologists) and public health officials who are required to understand COVDI-19 diagnosis and management as part of their clinical training or professional work. 606 $aCovid-19 vaccines 606 $aPublic policy 610 $aCommunicable Diseases 610 $aMedical 615 0$aCovid-19 vaccines. 615 0$aPublic policy. 676 $a362.1962414 700 $aMittal$b Neeraj$01682347 701 $aBhadada$b Sanjay Kumar$01721142 701 $aKatare$b O. P$01682349 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910825895903321 996 $aCOVID-19$94120392 997 $aUNINA